3
ALL2
Neupharma1
Reyon Pharmaceutical Co., LtdYear
3
ALL1
20212
2020DEALS // DEV.
3
ALL3
DevelopmentsCountry
3
ALL2
ITALY1
SOUTH KOREA3
ALL3
InapplicableTherapeutic Area
3
ALL3
Infections and Infectious DiseasesStudy Phase
3
ALL2
Phase I1
PreclinicalDeal Type
3
ALL3
InapplicableProduct Type
3
ALL3
AntibioticDosage Form
3
ALL2
Nasal Aerosol for Inhalation1
UndisclosedLead Product
3
ALL3
TeicoplaninTarget
3
ALL3
Cell wall peptidoglycan synthesisLead Product(s) : Teicoplanin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inhaled Teicoplanin Completed Phase 1 Clinical Trial in Cystic Fibrosis
Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.
Product Name : Teicoplanin Sandoz
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : Teicoplanin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Teicoplanin,Arbekacin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
REYON's Teicoplanin and Arbekacin Enter Preclinical Trials for COVID-19
Details : Teicoplanin is a glycopeptide antibiotic, which is being evaluated in combination with arbekacin sulfate for the treatment of covid-19.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 06, 2020
Lead Product(s) : Teicoplanin,Arbekacin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Teicoplanin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Food and Drug Administration granted Teicoplanin the PEDIATRIC Orphan Drug Designation
Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.
Product Name : Teicoplanin Sandoz
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Teicoplanin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable